Molecular determinants of biased agonism at the dopamine D₂ receptor.
暂无分享,去创建一个
Ralf C. Kling | Harald Hübner | Peter Gmeiner | R. Kling | P. Gmeiner | H. Hübner | Dietmar Weichert | C. Hiller | Ralf C Kling | A. Banerjee | Ashutosh Banerjee | Dietmar Weichert | Christine Hiller
[1] Arthur Christopoulos,et al. Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.
[2] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[3] Hualiang Jiang,et al. Structural Basis for Molecular Recognition at Serotonin Receptors , 2013, Science.
[4] J. Hieble,et al. Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives. , 1985, Journal of medicinal chemistry.
[5] P. Gmeiner,et al. Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor , 2011, Molecular Pharmacology.
[6] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[7] B. Mckittrick,et al. Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery. , 2014, Journal of medicinal chemistry.
[8] M. Fishman,et al. Activated mutants of the alpha subunit of G(o) promote an increased number of neurites per cell , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[9] S. Hjorth,et al. Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. , 1985, Journal of Medicinal Chemistry.
[10] Eric Trinquet,et al. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy , 2012, Proceedings of the National Academy of Sciences.
[11] H. Nakata,et al. Functional Characterization of Gαo Signaling through G Protein-Regulated Inducer of Neurite Outgrowth 1 , 2005, Molecular Pharmacology.
[12] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[13] A. Christopoulos,et al. A structure-activity analysis of biased agonism at the dopamine D2 receptor. , 2013, Journal of medicinal chemistry.
[14] R. A. Moyer,et al. An Opioid Agonist that Does Not Induce μ-Opioid Receptor—Arrestin Interactions or Receptor Internalization , 2007, Molecular Pharmacology.
[15] R. Lefkowitz,et al. When 7 transmembrane receptors are not G protein-coupled receptors. , 2005, The Journal of clinical investigation.
[16] Maria F. Sassano,et al. Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. , 2012, Journal of medicinal chemistry.
[17] R. Baldessarini,et al. Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. , 2013, Chemical reviews.
[18] R. Gainetdinov,et al. The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.
[19] P. Gmeiner,et al. Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. , 2008, Journal of medicinal chemistry.
[20] Olivier Lichtarge,et al. β-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the β2 Adrenergic Receptor* , 2006, Journal of Biological Chemistry.
[21] H. V. Van Tol,et al. Modulation of Intracellular Cyclic AMP Levels by Different Human Dopamine D4 Receptor Variants , 1995, Journal of neurochemistry.
[22] S. Nickolls,et al. Functional coupling of the human dopamine D2 receptor with Gαi1, Gαi2, Gαi3 and Gαo G proteins: evidence for agonist regulation of G protein selectivity , 2003 .
[23] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[24] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[25] Arthur Christopoulos,et al. Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry Perspective , 2014, Medicinal research reviews.
[26] Christopher G. Tate,et al. Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol , 2012, Structure.
[27] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[28] F. Boeckler,et al. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists. , 2005, Journal of medicinal chemistry.
[29] C. Spencer,et al. Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.
[30] P. Gmeiner,et al. Development of a bivalent dopamine D₂ receptor agonist. , 2011, Journal of medicinal chemistry.
[31] H. Jensen,et al. Microwave Irradiation as anEffective Means of Synthesizing Unsubstituted N-Linked 1,2,3-Triazolesfrom Vinyl Acetate and Azides , 2009 .
[32] J. Cannon. Structure-activity relationships of dopamine agonists. , 1983, Annual review of pharmacology and toxicology.
[33] K. Neve. Functional selectivity of G protein-coupled receptor ligands : new opportunities for drug discovery , 2009 .
[34] Cheng Zhang,et al. Irreversible Agonist-Beta2 Adrenoceptor Complex , 2011 .
[35] F. Wurm,et al. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. , 1996, Nucleic acids research.
[36] M. Sodeoka,et al. A New Route for the Preparationof Succinates , 2008 .
[37] Lisa Nguyen,et al. Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance , 2010, Journal of Pharmacology and Experimental Therapeutics.
[38] Ralf C. Kling,et al. Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. , 2013, Journal of medicinal chemistry.
[39] S. Rees,et al. Interactions of the alpha2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants. , 1997, The Biochemical journal.
[40] Susana R. Neves,et al. G Protein-regulated Inducer of Neurite Outgrowth (GRIN) Modulates Sprouty Protein Repression of Mitogen-activated Protein Kinase (MAPK) Activation by Growth Factor Stimulation* , 2012, The Journal of Biological Chemistry.
[41] Ravi Iyengar,et al. Regulation of neurite outgrowth by G(i/o) signaling pathways. , 2008, Frontiers in bioscience : a journal and virtual library.
[42] R. Gainetdinov,et al. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics , 2008, Proceedings of the National Academy of Sciences.
[43] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[44] P. Gmeiner,et al. Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions. , 2011, Journal of medicinal chemistry.
[45] S. Senogles. The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. , 1994, The Journal of biological chemistry.
[46] Arthur Christopoulos,et al. A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.
[47] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[48] R. Stevens,et al. Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.
[49] Kurt Wüthrich,et al. Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.
[50] Ralf C. Kling,et al. Functionally selective dopamine D₂, D₃ receptor partial agonists. , 2014, Journal of medicinal chemistry.
[51] Maarten G. Wolf,et al. g_membed: Efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation , 2010, J. Comput. Chem..
[52] P. Gmeiner,et al. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. , 2000, Journal of medicinal chemistry.
[53] T. Straatsma,et al. THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .
[54] P. Greengard,et al. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[55] A. Christopoulos,et al. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor. , 2014, Journal of medicinal chemistry.
[56] Harald Hübner,et al. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.
[57] Maria F. Sassano,et al. Discovery of β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy , 2011, Proceedings of the National Academy of Sciences.
[58] Peter Gmeiner,et al. Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor. , 2011, Journal of molecular biology.
[59] T. Kenakin,et al. Measurements of ligand bias and functional affinity , 2013, Nature Reviews Drug Discovery.
[60] L. Naylor,et al. Effect of Multiple Serine/Alanine Mutations in the Transmembrane Spanning Region V of the D2 Dopamine Receptor on Ligand Binding , 2000, Journal of neurochemistry.
[61] E. Davidov,et al. New Derivatives of L-Glutamine† , 1969 .
[62] Bruno Giros,et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.
[63] Gerrit Groenhof,et al. GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..
[64] K. Neve,et al. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. , 1998, Molecular pharmacology.
[65] T. Biden,et al. Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. , 1992, Molecular Endocrinology.
[66] Arthur Christopoulos,et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.